Longitudinal enrichment of eosinophilic esophagitis in children with AD: The MPAACH cohort. Journal of Allergy and Clinical Immunology. 2026; 157(4):999-1001.
Massively parallel analysis of genotype-dependent enhancer activity among atopic dermatitis genetic risk variants. Journal of Allergy and Clinical Immunology. 2025; 156(6):1600-1613.
Genome-wide cross-trait analysis of heterogeneous outcomes in early life atopic dermatitis. Pediatric Allergy and Immunology. 2025; 36(12):e70253.
Bioluminescent monitoring of a co-culture model of pathogen growth to identify a novel probiotic bacterium. BMC Research Notes. 2025; 18(1):434.
Early-life wheeze trajectories are associated with distinct asthma transcriptomes later in life. Journal of Allergy and Clinical Immunology. 2025; 156(3):640-650.
Skin Staphylococcus aureus detection and relationship to atopic dermatitis outcomes using culture and metagenomic sequencing. Scientific Reports. 2025; 15(1):17606.
Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children. JAMA Network Open. 2025; 8(2):e2462176.
Joint genotype and ancestry analysis identify novel loci associated with atopic dermatitis in African American population. HGG Advances. 2024; 5(4):100350.
Co-Expression Network and Machine Learning Analysis of Transcriptomics Data Identifies Distinct Gene Signatures and Pathways in Lesional and Non-Lesional Atopic Dermatitis. Journal of Personalized Medicine. 2024; 14(9).
Massively Parallel Analysis of Genotype-Dependent Enhancer Activity Among Atopic Dermatitis Genetic Risk Variants. . 2024.
Regulation of MYC by CARD14 in human epithelium is a determinant of epidermal homeostasis and disease. Cell reports. 2024; 43(8):114589.
Filaggrin loss-of-function variants are associated with atopic dermatitis phenotypes in a diverse, early-life prospective cohort. JCI Insight. 2024; 9(9).
Temporal relationships between Staphylococcus aureus colonization, filaggrin expression, and pediatric atopic dermatitis. Allergy. European Journal of Allergy and Clinical Immunology. 2024; 79(1):104-115.
Pirfenidone as a potential antifibrotic injectable for Dupuytren's disease. Pharmaceutical Development and Technology. 2022; 27(2):242-250.